Research
Hormonal
Insulin resistance is a key feature of PCOS, but routine clinical measurement of insulin resistance is not recommended due to the inaccuracy of currently available measures.
While insulin resistance is common in PCOS, current clinical tests for it are not accurate enough to guide individual treatment decisions. Focus on lifestyle changes (diet, exercise) which improve insulin sensitivity, rather than seeking specific insulin blood tests.
ModerateRefutesMEDIUM confidence
Insulin resistance is recognized as a key feature of PCOS, yet routinely available measures of insulin resistance are inaccurate and clinical measurement is not currently recommended.
Why this rating
Based on the guideline's assessment of the inaccuracy of available tests.
Source
Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome
Helena Teede et al. · Human Reproduction · 2023
DOI 10.1093/humrep/dead156
clinical_guidelineCited 183×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Anti-Müllerian Hormone (AMH) testing can be used as an alternative to ultrasound for diagnosing PCOS in adults, offering a low-cost, convenient option without evidence of overdiagnosis.Good
- Lifestyle management, specifically focusing on healthy lifestyle, emotional wellbeing, and quality of life, is a foundational recommendation for the assessment and management of PCOS, with explicit attention to avoiding weight stigma.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →